{"denoms":[{"counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"45"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"55"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"206"}],"units":"Participants"}],"groups":[{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"BG000","title":"Anaplastic Thyroid Cancer (ATC)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"BG001","title":"Biliary Tract Cancer (BTC)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"BG002","title":"Gastrointestinal Stromal Tumor (GIST)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"BG003","title":"Low Grade (WHO G1/G2) Glioma (LGG)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"BG004","title":"High Grade (WHO G3/G4) Glioma (HGG)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"BG005","title":"Adenocarcinoma of the Small Intestine (ASI)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"BG006","title":"Hairy Cell Leukemia (HCL)"},{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"BG007","title":"Multiple Myeloma (MM)"},{"description":"Total of all reporting groups","id":"BG008","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.53","value":"69.6"},{"groupId":"BG001","spread":"11.88","value":"57.0"},{"comment":"Only one participant analyzed","groupId":"BG002","spread":"NA","value":"77.0"},{"groupId":"BG003","spread":"11.51","value":"33.1"},{"groupId":"BG004","spread":"14.70","value":"41.9"},{"groupId":"BG005","spread":"3.21","value":"58.3"},{"groupId":"BG006","spread":"10.77","value":"64.8"},{"groupId":"BG007","spread":"6.89","value":"66.9"},{"groupId":"BG008","spread":"16.40","value":"57.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"22"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"90"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"23"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"47"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"116"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"4"}]}],"title":"African American/African Heritage"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}],"title":"Asian - Central/South Asian Heritage"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"17"}]}],"title":"Asian - East Asian Heritage"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"7"}]}],"title":"Asian - Japanese Heritage"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"4"}]}],"title":"Asian - South East Asian Heritage"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"5"}]}],"title":"White - Arabic/North African Heritage"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"32"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"48"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"157"}]}],"title":"White - White/Caucasian/European heritage"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"10"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"25"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"72"}],"title":"Grade 0"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"27"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"118"}],"title":"Grade 1"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"16"}],"title":"Grade 2"}]}],"description":"The Eastern Cooperative Oncology Group Performance Status (ECOG PS) score classifies participants according to their functional impairment, with scores ranging from 0 (fully active) to 5 (dead). ECOG PS: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}]}